

View this retrospective in your internet browser

In 2023, Op2Lysis continued its research and development efforts to offer a therapeutic solution to the unmet medical need of hemorrhagic stroke. This retrospective covers the team's progress towards this goal. The following sections describe the company's technical progress, innovation funding and recognition in the field of intracerebral hemorrhage.

We would also like to take this opportunity to wish all our investors and partners, readers and communities a very Happy New Year 2024.



Technical progress and successes.



In 2023, we successfully completed a 50x scale-up of OptPA production (from a 2L reactor to a 100L reactor), producing our first GMP-like batch dedicated to toxicology program which is now initiated. The master cell bank (the source of our OptPA active substance) was also successfully released, and the vials required for all production, both for clinical development and for commercial sales, are now available.

Analytical development, which is necessary for the regulatory acceptance of our product before it enters the clinic, has also been at the heart of our activity. This development is almost complete for OptPA and we are glad to report that impressive progress has also been accomplished for the formulated product.


Corporate progress & Fundings obtained in 2023.



The technical advances described above have mainly been **supported by private funding from the historical investors, and public fundings** from (i) the European EIC (European Innovation Council) accelerator, for which we have triggered the first two tranches ($\leq 2m$), (ii) the Walloon region (DGO6 - Op2Wallonie 2 - $\leq 1.6m$) and (iii) France through the Deeptech development aid program (bpifrance - ADD - $\leq 1.5m$). We have **initiated intensive fund-raising activity in 2023 to accelerate our development.** As part of the Accelerator program, the EIC fund has been approached for an equity co-investment (series A) in 2024.

Our technical progress and the know-how we have developed have also been recognized through **two collaborative academic programs**, a University Hospital Research program coordinated by Prof C. Cordonnier (RHU TIPITCH - Lille France) in which Op2Lysis is a partner, and a program funded by the French National Research Agency (ANR) in collaboration with Inserm unit U1237 (Caen, France) to initiate work in support of new indications and an extension of the current portfolio.

Communications and recognition.



The company has been invited to present its technology at a number of international conferences, including Bio Europe Spring, BIO trinity and BIOVARIA with the support of the Walloon health cluster (BioWin), BioEquity Europe, BIO international under the EIC Europe pavilion, BIO Europe and Biofit with the support of the Walloon Export Agency (AWEX). **Op2Lysis has been nominated in the «Best StartUp» category of the renowned Prix Galien USA 2023.**

The **scientific work was published in BRAIN**, a renowned journal in clinical neurology ranked 5th among 212 esteemed journals in the field of translational neuroscience.

Op2Lysis was also invited to present its results at the specialist WICH (World IntraCranial Hemorrhage) congress, held in Toronto in the presence of all the international experts in the field, and to share Op2Lysis's experience in obtaining orphan designation at a prestigious academy-industry meeting on the occasion of the congress.







